ZNF658B: A Potential Drug Target and Biomarker (G401509)
ZNF658B: A Potential Drug Target and Biomarker
Introduction
Zinc finger proteins (ZFPs) are a family of transcription factors, which play a crucial role in gene regulation and development. ZNF658B, also known as zinc finger protein 658B (pseudogene), is a ZFP that has been identified as a potential drug target and biomarker. In this article, we will explore the biology of ZNF658B, its potential drug targets, and its potential as a biomarker.
Biography of ZNF658B
ZNF658B is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a zinc finger protein that contains a characteristic zinc finger domain, which is responsible for its unique structure and function. The zinc finger domain is a transmembrane domain that contains a characteristic Rossmann-fold, which is known for its ability to interact with various transcription factors and proteins.
Expression and regulation
ZNF658B is a widely expressed protein that is expressed in various tissues, including brain, heart, and muscle. It is a nuclear protein that is predominantly expressed in the brain, where it is highly expressed in the frontal cortex, hippocampus, and cerebellum. ZNF658B is also expressed in the heart and muscle, where it is expressed at lower levels.
ZNF658B is regulated by various factors, including transcription factors, miRNA and DNA methylation. miRNA is an RNA molecule naturally present in cells that can regulate gene expression by binding to the mRNA of target genes. The mRNA of ZNF658B can be regulated through the miRNA pathway, which indicates that ZNF658B plays an important role in the regulation of gene expression regulated by miRNA.
Function and mechanism of action
ZNF658B is a zinc finger transcription factor with characteristics such as zinc finger domain, Rossmann-fold and hydrophobic interactions. The zinc finger domain is the most striking feature of ZNF658B, which can bind to specific sequences in DNA, thereby enhancing DNA binding. This binding force helps enhance the affinity of ZNF658B to DNA, thereby increasing the binding ability of ZNF658B to transcription factors.
The Rossmann-fold of ZNF658B is a conserved protein domain with conserved secondary structure characteristics. This domain is rich in hydrogen bonds and hydrophobic interactions, allowing ZNF658B to bind to specific regions in DNA and enhance this binding.
pharmacological significance
ZNF658B is a potential drug target because it is closely related to the occurrence and development of various diseases. Studies have found that overexpression of ZNF658B is associated with the occurrence of a variety of neurological diseases, including depression, Alzheimer's disease, Parkinson's disease and dystonia. In addition, the expression level of ZNF658B is also closely related to the development of various tumor types, including lung cancer, liver cancer, breast cancer and other tumors.
In addition, ZNF658B also interacts with a variety of drugs, including antipsychotics, antidepressants, and antitumor drugs. These drugs may regulate the expression level of ZNF658B by inhibiting its function, thereby affecting the therapeutic effect of the disease.
as biomarkers
As a protein, ZNF658B can be used as a biomarker for various diseases. For example, ZNF658B can be used as a diagnostic biomarker for diseases such as depression, Alzheimer's disease, Parkinson's disease, and dystonia. In addition, ZNF658B can also be used as a tumor biomarker for the diagnosis and treatment of lung cancer, liver cancer, breast cancer and other tumors.
Conclusion
ZNF658B is a widely
Protein Name: Zinc Finger Protein 658B (pseudogene)
Functions: May be involved in transcriptional regulation
The "ZNF658B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF658B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670 | ZNF670-ZNF695 | ZNF671 | ZNF672 | ZNF674 | ZNF674-AS1 | ZNF675 | ZNF676 | ZNF677 | ZNF678 | ZNF679 | ZNF680 | ZNF681 | ZNF682 | ZNF683 | ZNF684 | ZNF687 | ZNF688 | ZNF689 | ZNF69 | ZNF691 | ZNF692 | ZNF695 | ZNF696 | ZNF697 | ZNF699 | ZNF7 | ZNF70 | ZNF700 | ZNF701 | ZNF702P | ZNF703 | ZNF704 | ZNF705A | ZNF705B | ZNF705CP | ZNF705EP | ZNF705G | ZNF706 | ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776
